Burjeel Holdings announced an association with Paige, an American leader in the technology of the general, to improve access to advanced cancer diagnoses.
The EUA’s highest of medical care said it will implement the US company’s solutions in its health network.
Burjel, Paige Jinin forces
The Association also seeks to address the global scarcity of pathologists and accelerate access to rapid and reliable gravels, participulate in unattended communities and emerging markets.
Paige has developed a set of AI applications that support diagnostic decision making in cancer pathology.
“By incorporating the AI of the next gene into our pathology services, our goal is to improve the speed and precision of vnosis, allowing more effective treatment decisions,” said John Sunil, CEO of the group or burjel holdings.
“This association also reflects our mission to provide world -class care for technology to emerging markets,” he said.
Peter Hamilton, general manager of Diagnosis, Paige, said that Burjel Holdings’ commitment to innovation and equitable care throughout the Mena region makes them a powerful ally to help the company close the diagnostic gaps and bring fasters, the benefits of our AI AI Atit,
“This association helps to fulfill our mission to make cancer diagnoses of the next general access worldwide and align with our vision of standardizing access to avant -garde diagnoses at a global scale,” he said.
Paige has obtained multiple regulatory achievements in AI for the pathology, including the designation of innovative devices of the FDA for Paige Pancance Detect, Paige Breast Lymph -node and Paige Prostate Detect.
Burjeel Holdings said it will implement thesis AI applications together with Paige Omniscreen, which simultaneously shows more than 1,600 molecular biomarkers to support the integral diagnosis of cancer and a more personalized treatment.
